Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.6052W HIGH $50.74
Volume
66.68 K
Value Traded
66.48 K
Short % Float
0.37%
+3.05%Week
-16.18%1 Month
-41.09%3 Month
-40.72%6 Month
-99.45%5 Year
-99.48%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
54.01 M
EPS (TTM)
-15.01
P/E Ratio
-
Ent. Value
2.95 M
Total Shares
9.39 M
Float Shares
6.37 M
Insiders
32.39%
Institutions
56.73%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
LONA Catalyst Timeline
Dated clinical, regulatory and corporate events for LeonaBio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for LeonaBio, Inc.
172Total events
7Upcoming
31Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationPresentation
Panel presentation at BIO International Convention: The Future of Oncology Trials
oncologysource ↗
◆Oral PresentationATH-1105Presentation
Oral presentation at 5th Annual ALS Drug Development Summit: Advancing ATH-1105 in ALS
ALSsource ↗
●Oral PresentationLasofoxifenePresentation
Virtual Key Opinion Leader event
ER-positive (ER+), HER2-negative, ESR1-mutated metastatic breast cancersource ↗
▲Enrollment UpdateLasofoxifeneTrial
ELAINE-3 trial more than 50% enrolled
metastatic breast cancersource ↗
▲First Patient DosedATH-1105Trial
First-in-human Phase 1 trial enrolled 80 healthy volunteers
healthy volunteerssource ↗
◆Trial InitiationATH-1105Trial
Phase 2 trial initiation planned for ATH-1105 in ALS patients
ALSsource ↗
▲Oral PresentationLasofoxifenePresentation
Nonclinical data presented at AACR Annual Meeting 2026 (AACR26)
ER-positive, HER2-negative, ESR1-mutated metastatic breast cancersource ↗
▲Trial CompletionbrelgometonTrial
Phase 1 trial of brelgometon completed
amyotrophic lateral sclerosis (ALS)source ↗
▲Partnership / LicenseLasofoxifeneCorporate
Exclusive global license from Sermonix Pharmaceuticals for lasofoxifene
metastatic breast cancersource ↗
▼Equity OfferingCorporate
Upfront $90 million private placement financing with potential additional $146 million from warrants
▲Enrollment MilestoneLasofoxifeneTrial
ELAINE-3 trial greater than 50% enrolled
metastatic breast cancersource ↗
▲AcquisitionLasofoxifeneCorporate
Exclusive global license for lasofoxifene from Sermonix Pharmaceuticals
metastatic breast cancersource ↗
▲Partnership / LicenseLasofoxifeneCorporate
Exclusive global license acquired from Sermonix Pharmaceuticals
▲Oral PresentationATH-1105Presentation
Phase 1 results presented at ALS Nexus 2025 conference in August 2025
ALSsource ↗
◆Oral PresentationATH-1105Presentation
Presentation at ALS Drug Development Summit
amyotrophic lateral sclerosis (ALS)source ↗
▲Oral PresentationATH-1105Presentation
Data from Phase 1 trial of ATH-1105 presented at ALS Drug Development Summit
ALSsource ↗
◆First Patient DosedATH-1105Trial
On-track to enable dosing ALS patients in 2025
amyotrophic lateral sclerosis (ALS)source ↗
▼Equity OfferingCorporate
Private placement financing of common stock and warrants with gross proceeds of $90 million; cash-exercisable warrants potentially providing up to an additional $146 million
▲Oral PresentationATH-1105Presentation
Phase 1 data presented at 4th Annual ALS Drug Development Summit
ALSsource ↗
◆Trial CompletionATH-1105Trial
Completion of Phase 1 trial of ATH-1105 in healthy volunteers
Healthy volunteerssource ↗
▼Program DiscontinuationFosgonimetonDiscontinuedCorporate
Paused further development of fosgonimeton
Alzheimer's diseasesource ↗
▲Trial CompletionATH-1105Trial
Completed healthy volunteer Phase 1 clinical study of ATH-1105
amyotrophic lateral sclerosis (ALS)source ↗
◆Oral PresentationFosgonimetonDiscontinuedPresentation
Full analysis of LIFT-AD results to be presented at CTAD 2024
Alzheimer's diseasesource ↗
◆Oral PresentationFosgonimetonDiscontinuedPresentation
Oral presentation of LIFT-AD data at CTAD
mild-to-moderate Alzheimer's diseasesource ↗
◆Topline ReadoutFosgonimetonDiscontinuedClinical Data
Topline data readout from Phase 2/3 LIFT-AD trial of fosgonimeton
Alzheimer's diseasesource ↗
▼Topline ReadoutFosgonimetonDiscontinuedClinical Data
Topline results from Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer's disease
Alzheimer's diseasesource ↗
▼Topline ReadoutFosgonimetonDiscontinuedClinical Data
Topline results from LIFT-AD Phase 2/3 trial of fosgonimeton
Alzheimer's diseasesource ↗
▼Trial DiscontinuedFosgonimetonDiscontinuedTrial
Paused further development of fosgonimeton including open label extension
Alzheimer's diseasesource ↗
▼Program DiscontinuationFosgonimetonDiscontinuedCorporate
Paused further development of fosgonimeton
Alzheimer's diseasesource ↗
●Last Patient Last VisitFosgonimetonDiscontinuedTrial
Last patient dosed in LIFT-AD study
mild-to-moderate Alzheimer's diseasesource ↗
●Poster PresentationFosgonimetonDiscontinuedPresentation
Poster presentations at AAIC 2024 on fosgonimeton
Alzheimer's diseasesource ↗
▲First Patient DosedATH-1105Trial
First patient dosed in Phase 1 healthy volunteer study of ATH-1105
amyotrophic lateral sclerosis (ALS)source ↗
▲Enrollment MilestoneATH-1105Trial
Completed first cohort of healthy volunteers in Phase 1 trial
Healthy volunteerssource ↗
●Enrollment CompleteATH-1105Trial
First cohort of healthy volunteers completed
amyotrophic lateral sclerosis (ALS)source ↗
Past FDA Catalysts and PDUFA Decisions
How LONA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$93M
Pipeline Value
Fair Value
Valuation Signal
6
Drugs Scored
1.7x
rNPV / MCap
Top 45%
Micro Cap(rank 298 of 660)
Percentile Rank
LeonaBio, Inc. faces pipeline headwinds (38/100), with $1.6B risk-adjusted pipeline value, led by Lasofoxifene in Metastatic Breast Cancer (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lasofoxifene Small moleculeNCT05696626 | Metastatic Breast Cancer | Phase 3 | RECRUITING | 600 | Apr 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every LONA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ATH-1105 | ALS | Phase 1 | 2025-11-06 | favorable safety profile; well tolerated in both single and multiple ascending dose studies; dose proportional pharmacokinetics; CNS penetrationRead More | Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Continuing to explore strategic alternatives focusing on maximizing stockholder value Presented results from Phase 1 clinical trial Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLCDirector, 10% Owner | Grant/Award | 28,000 28,000 held | $0.00 | 06/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LONA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LONA for Q2 2026. | ||||
LONA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LONA ranks across every disease it competes in
Competitive Position is a premium feature
See how LONA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLONA News
LONALeonaBio to Participate in Cantor Global Healthcare Conference 2026
LeonaBio, a clinical-stage biopharmaceutical company, will participate in the Cantor Global Healthcare Conference 2026 from September 9-11 in New York. The company's management will engage in a fireside chat on September 11, discussing their innovative therapies for diseases with high unmet medical needs. A live webcast will be available for investors.
Read more →LONALeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
LeonaBio reported its Q2 2026 financial results, highlighting progress in its Phase 3 ELAINE-3 clinical trial for lasofoxifene in treating ESR1-mutated metastatic breast cancer. The company has enrolled 495 patients and expects to complete enrollment by Q4 2026, with topline data anticipated in 2H 2027. Despite a net loss of $19 million, LeonaBio remains optimistic about its pipeline and financial outlook.
Read more →LONALeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
LeonaBio is set to present findings on lasofoxifene for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer at DAVA Oncology’s summit. The company is on schedule to complete enrollment for the Phase 3 ELAINE-3 clinical trial by the end of 2026, with expected topline data in the second half of 2027.
Read more →LONALeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
LeonaBio presented its drug candidate brelgometon (ATH-1105) at the 5th Annual ALS Drug Development Summit. The presentation outlined its mechanism of action and supportive Phase 1 clinical data, paving the way for a Phase 2 proof-of-concept study set to begin in late 2026. Brelgometon aims to address the significant unmet medical needs in ALS.
Read more →LONALeonaBio to Participate in Upcoming Medical and Industry Meetings in June
LeonaBio, a clinical-stage biopharmaceutical company, will participate in two key industry meetings in June 2026. The first is the 5th Annual ALS Drug Development Summit in Boston, where they will present on their drug ATH-1105. The second is the BIO International Convention in San Diego, focusing on oncology trials and patient survival.
Read more →LONALeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
LeonaBio, a clinical-stage biopharmaceutical company, has appointed Fred Callori, Natalie Holles, and Peter B. Silverman to its Board of Directors as of May 5, 2026. These appointments are expected to strengthen the company's leadership and align with its focus on developing novel therapeutics for unmet medical needs. The company also acknowledged the retirement of John Fluke, Jr., who served on the board since 2014.
Read more →LONALeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations
LeonaBio, a clinical-stage biopharmaceutical company, reported its first-quarter financial results for 2026 and highlighted its ongoing commitment to developing lasofoxifene, a selective estrogen receptor modulator, for treating metastatic breast cancer with ESR1 mutations. The company expects to complete enrollment in its Phase 3 trial by Q4 2026 and anticipates topline data in the second half of 2027. Additionally, LeonaBio plans to initiate a Phase 2 trial for ATH-1105 targeting ALS patients in the latter half of 2026, with promising results from earlier studies. Recent leadership appointments are also part of the company's strategic focus moving forward.
Read more →LONALeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
LeonaBio is hosting a virtual Key Opinion Leader event to discuss lasofoxifene's potential in treating treatment-resistant ER+/HER2- metastatic breast cancer. The event will feature insights from leading physicians and is timed with the expected completion of enrollment in the ELAINE-3 Phase 3 study. Data from this study is anticipated in the second half of 2027.
Read more →LONAIndependent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data
LeonaBio presented findings on lasofoxifene at the AACR Annual Meeting 2026, highlighting its protective effects against hormone withdrawal-induced bone loss and its anti-tumor efficacy in ER+ breast cancer models. The research aligns with LeonaBio's ongoing Phase 3 ELAINE-3 trial, supporting lasofoxifene's potential as a therapeutic candidate for patients with ESR1 mutations. The data reinforces the drug's dual action of combating tumor growth while preserving bone integrity.
Read more →LONA▼ -7.3%on this news
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
LeonaBio reported its financial results for 2025, highlighting the acquisition of lasofoxifene, a promising treatment for breast cancer. The company raised $90 million in funding, with the possibility of an additional $146 million. They expect to complete enrollment in a Phase 3 trial by late 2026 and initiate a Phase 2 study for ALS in the same timeframe. Leadership expresses confidence in their evolving pipeline and future milestones.
Read more →LONALeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
LeonaBio has appointed Mark F. Kubik as Chief Business Officer to lead its business development strategy. Kubik, who has over 25 years of experience in the biopharmaceutical industry, previously served as a strategic consultant for the company. His role will be crucial as LeonaBio advances its Phase 3 development program for lasofoxifene, targeting treatment-resistant metastatic breast cancer.
Read more →LONAAthira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker LONA New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation
Athira Pharma has officially changed its name to LeonaBio, Inc. and adopted the new ticker symbol LONA, effective January 12, 2026. This change follows the company's acquisition of rights to develop losofoxifene, a promising drug for the treatment of metastatic breast cancer currently in Phase 3 trials. LeonaBio aims to focus on addressing unmet medical needs through its innovative pipeline, which also includes candidates for neurodegenerative diseases. The company plans to advance its therapies with considerable financial backing and is committed to improving treatment outcomes for patients with serious diseases.
Read more →LONAAthira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Athira Pharma has announced an exclusive license for the development of lasofoxifene, a selective estrogen receptor modulator, focused on treating metastatic breast cancer. The company secured $90 million in upfront financing, with potential total financing of $236 million, to support the Phase 3 development program aimed at patients with ESR1 mutations. The ongoing ELAINE-3 clinical trial is already over 50% enrolled, with topline data expected in mid-2027. This development represents a significant opportunity for Athira to enhance its pipeline and potentially shape treatment standards in breast cancer care.
Read more →LONAAthira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Continuing to explore strategic alternatives focusing on maximizing stockholder value
Athira Pharma provided its financial results for Q3 2025, highlighting a favorable safety profile for its drug ATH-1105 in a Phase 1 clinical trial targeting ALS. The company is exploring strategic alternatives to maximize shareholder value amidst ongoing clinical developments. Athira reported a net loss of $6.6 million for the quarter and decreased cash reserves, raising potential concerns about funding future initiatives. However, the positive trial results suggest a promising future for ATH-1105 in the treatment of neurodegenerative diseases.
Read more →LONAAthira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Athira Pharma reported its second quarter 2025 financial results, highlighting positive data from its Phase 1 trial of ATH-1105. The trial exhibited a favorable safety profile and dose proportional pharmacokinetics, supporting the drug's continued development for ALS. However, Athira is exploring strategic alternatives due to the underperformance of its previous drug candidate and decreasing cash reserves. The CEO expressed optimism regarding the future plans for ATH-1105 and aims to initiate subsequent trials in ALS patients soon.
Read more →LONAAthira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
Athira Pharma reported its first quarter 2025 financial results, highlighting the completion of a Phase 1 clinical study for ATH-1105, a potential treatment for ALS. The study demonstrated a favorable safety profile and is expected to allow dosing in ALS patients by late 2025. The company is also exploring strategic alternatives following setbacks with its Alzheimer’s treatment candidate, fosgonimeton. Financially, Athira experienced a loss but has made cuts in R&D expenses.
Read more →LONAAthira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
Athira Pharma, Inc. reported financial results for 2024 along with updates on its pipeline. The Phase 1 clinical study of ATH-1105, aimed at treating ALS, was completed successfully, showing a favorable safety profile. The company plans to start dosing ALS patients by 2025 based on preclinical improvements seen in nerve and motor function. However, development of another candidate, fosgonimeton, has been paused following the LIFT-AD trial results, which did not meet its endpoints. Athira is exploring strategic alternatives to maximize stockholder value.
Read more →LONAAthira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025
Athira Pharma reported its financial results for Q3 2024 and provided updates on its clinical pipeline, particularly focusing on ATH-1105, a drug candidate for ALS. The company expects to complete Phase 1 trials of ATH-1105 by the end of 2024 and plans to start dosing ALS patients in 2025. Despite a strong pipeline, the company faced challenges as its Alzheimer's drug candidate, fosgonimeton, did not meet key trial endpoints and is currently put on hold. Financially, Athira reported a net loss of $28.7 million for the quarter.
Read more →LONAAthira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical
Athira Pharma has announced a strategic focus on advancing ATH-1105, an orally administered drug, for treating neurodegenerative diseases, particularly ALS and Alzheimer's. The company is implementing cost containment measures including a workforce reduction, which will help extend its cash runway into early 2026. ATH-1105 has demonstrated promising preclinical results, suggesting neuroprotective benefits, while the ongoing Phase 1 clinical trial aims to assess its safety and tolerability. The company also acknowledges potential risks ahead, including regulatory approvals and recruitment for clinical studies.
Read more →LONAAthira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease LIFT-AD trial did not meet primary endpoint of GST and key secondar
Athira Pharma reported topline results from its Phase 2/3 LIFT-AD trial evaluating fosgonimeton for mild-to-moderate Alzheimer's disease. While the trial did not meet its primary or key secondary endpoints, pre-specified subgroup analyses suggested potential benefits in certain patient groups. Biomarker data indicated improvements consistent with the drug's neuroprotective actions. Despite these encouraging findings, the overall clinical significance was not demonstrated, leading to challenges in interpreting fosgonimeton's efficacy.
Read more →About LeonaBio, Inc.
Headquarters18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011
BIOPHARMAWATCH ELITE PLUS
Trade the next LONA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime